Executive interview – Immunicum

Published on 11 February 2019

Immunicum is a clinical-stage immuno-oncology company based in Stockholm, Sweden. The company is developing an allogeneic off-the-shelf dendritic cell immune activator (immune primer) for use in combination with tyrosine kinase inhibitors and checkpoint inhibitors in various solid tumour indications. In this video, the company’s chief executive officer Carlos de Sousa explains the recent R&D progress and expected newsflow.

Share this with friends and colleagues